{"drugs":["Aflibercept","Eylea"],"mono":{"0":{"id":"930048-s-0","title":"Generic Names","mono":"Aflibercept"},"1":{"id":"930048-s-1","title":"Dosing and Indications","sub":[{"id":"930048-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Diabetic macular edema:<\/b> 2 mg (0.05 mL) INTRAVITREALLY every 4 weeks for 5 injections, then 2 mg INTRAVITREALLY every 8 weeks; adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection<\/li><li><b>Diabetic macular edema - Diabetic retinopathy:<\/b> 2 mg (0.05 mL) INTRAVITREALLY every 4 weeks for 5 injections, then 2 mg INTRAVITREALLY every 8 weeks; give adequate anesthesia and a topical broad-spectrum microbicide prior to the injection<\/li><li><b>Exudative age-related macular degeneration:<\/b> 2 mg (0.05 mL) INTRAVITREALLY every 4 weeks for 12 weeks, then once every 8 weeks; adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection<\/li><li><b>Macular retinal edema - Thrombosis of retinal vein:<\/b> 2 mg (0.05 mL) INTRAVITREALLY once every 4 weeks; adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection<\/li><\/ul>"},{"id":"930048-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in pediatric patients "},{"id":"930048-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>gender:<\/b> dose adjustment not necessary<\/li><li><b>geriatric:<\/b> dose adjustment not necessary<\/li><\/ul>"},{"id":"930048-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Diabetic macular edema<\/li><li>Diabetic macular edema - Diabetic retinopathy<\/li><li>Exudative age-related macular degeneration<\/li><li>Macular retinal edema - Thrombosis of retinal vein<\/li><\/ul>"}]},"3":{"id":"930048-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930048-s-3-9","title":"Contraindications","mono":"<ul><li>active intraocular inflammation<\/li><li>hypersensitivity to aflibercept or any component of the product<\/li><li>ocular or periocular infections<\/li><\/ul>"},{"id":"930048-s-3-10","title":"Precautions","mono":"<ul><li>Hematologic:<\/li><li>-- arterial thromboembolic events (eg, nonfatal stroke, nonfatal myocardial infarction, vascular death) have been reported<\/li><li>Ophthalmic:<\/li><li>-- endophthalmitis and retinal detachments have been reported<\/li><li>-- acute increases in intraocular pressure have been reported within 60 minutes of administration; monitoring recommended<\/li><li>-- sustained increases in intraocular pressure have been reported after repeated administration; monitoring recommended<\/li><\/ul>"},{"id":"930048-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930048-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930048-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Ophthalmic:<\/b>Conjunctival hemorrhage (12% to 31%), Corneal erosion (2% to 7%), Pain in eye (4% to 13%), Vitreous floaters (1% to 8%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction<\/li><li><b>Hematologic:<\/b>Arterial thrombosis (Up to 6.4%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (Less than 1%)<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident<\/li><li><b>Ophthalmic:<\/b>Cataract (Up to 19%), Endophthalmitis (Less than 1%), Raised intraocular pressure (2% to 9%), Retinal detachment (Less than 1%), Retinal tear (Less than 1%), Vitreous detachment (2% to 8%)<\/li><\/ul>"},"6":{"id":"930048-s-6","title":"Drug Name Info","sub":{"0":{"id":"930048-s-6-17","title":"US Trade Names","mono":"Eylea<br\/>"},"2":{"id":"930048-s-6-19","title":"Class","mono":"Ophthalmologic Agent<br\/>"},"3":{"id":"930048-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930048-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930048-s-7","title":"Mechanism Of Action","mono":"Aflibercept binds to the angiogenic vascular endothelial growth factors (VEGF), VEGF-A, and placental growth factor (PIGF), to inhibit their binding to receptor tyrosine kinases and activation of VEGF-A, thereby inhibiting neovascularization and vascular permeability <br\/>"},"8":{"id":"930048-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"930048-s-8-23","title":"Absorption","mono":"Tmax: 1 to 3 days (free aflibercept) <br\/>"},"1":{"id":"930048-s-8-24","title":"Distribution","mono":"Vd: 6 L (free aflibercept) <br\/>"},"4":{"id":"930048-s-8-27","title":"Elimination Half Life","mono":"5 to 6 days (free aflibercept) <br\/>"}}},"9":{"id":"930048-s-9","title":"Administration","mono":"<b>Intravitreal<\/b><br\/><ul><li>intended for single-use only; discard any unused product<\/li><li>use a new vial if the contralateral eye requires treatment<\/li><li>use 5-micron filter needle to withdrawal aflibercept and switch to a 30-gauge, 0.5-inch needle for intravitreal injection<\/li><\/ul>"},"10":{"id":"930048-s-10","title":"Monitoring","mono":"<ul><li>maintenance of visual acuity indicates efficacy<\/li><li>intraocular pressure elevation (eg, optic nerve head perfusion or tonometry); immediately after injection<\/li><\/ul>"},"11":{"id":"930048-s-11","title":"How Supplied","mono":"<b>Eylea<\/b><br\/>Intraocular Solution: 40 MG\/ML<br\/>"},"13":{"id":"930048-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid driving or other activities requiring clear vision until visual function has returned to normal.<\/li><li>This drug may cause conjunctival hemorrhage, eye pain, cataracts, vitreous detachment, vitreous floaters, and increased intraocular pressure.<\/li><li>Instruct patient to immediately report signs or symptoms of endophthalmitis or retinal detachment (eye redness or pain, light sensitivity, or vision changes).<\/li><\/ul>"}}}